160 related articles for article (PubMed ID: 38150033)
21. Progress on molecular biomarkers and classification of malignant gliomas.
Zhang C; Bao Z; Zhang W; Jiang T
Front Med; 2013 Jun; 7(2):150-6. PubMed ID: 23681890
[TBL] [Abstract][Full Text] [Related]
22. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
23. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
[TBL] [Abstract][Full Text] [Related]
24. Identification of WHO II/III Gliomas by 16 Prognostic-related Gene Signatures using Machine Learning Methods.
Wu YM; Sa Y; Guo Y; Li QF; Zhang N
Curr Med Chem; 2022; 29(9):1622-1639. PubMed ID: 34455959
[TBL] [Abstract][Full Text] [Related]
25. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets.
Fuller GN; Hess KR; Rhee CH; Yung WK; Sawaya RA; Bruner JM; Zhang W
Brain Pathol; 2002 Jan; 12(1):108-16. PubMed ID: 11771519
[TBL] [Abstract][Full Text] [Related]
26. Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling.
Zhang CB; Zhu P; Yang P; Cai JQ; Wang ZL; Li QB; Bao ZS; Zhang W; Jiang T
Oncotarget; 2015 Nov; 6(34):36643-51. PubMed ID: 26436699
[TBL] [Abstract][Full Text] [Related]
27. ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
Hirata K; Terasaka S; Shiga T; Hattori N; Magota K; Kobayashi H; Yamaguchi S; Houkin K; Tanaka S; Kuge Y; Tamaki N
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):760-70. PubMed ID: 22307533
[TBL] [Abstract][Full Text] [Related]
28. Molecular profiles for insular low-grade gliomas with putamen involvement.
Zhou C; Wang Y; Liu X; Liang Y; Fan Z; Jiang T; Wang Y; Wang L
J Neurooncol; 2018 Jul; 138(3):659-666. PubMed ID: 29556911
[TBL] [Abstract][Full Text] [Related]
29. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
30. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
31. A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma.
Rao SA; Srinivasan S; Patric IR; Hegde AS; Chandramouli BA; Arimappamagan A; Santosh V; Kondaiah P; Rao MR; Somasundaram K
PLoS One; 2014; 9(1):e85200. PubMed ID: 24475040
[TBL] [Abstract][Full Text] [Related]
32. Clonal analysis of gliomas.
Kattar MM; Kupsky WJ; Shimoyama RK; Vo TD; Olson MW; Bargar GR; Sarkar FH
Hum Pathol; 1997 Oct; 28(10):1166-79. PubMed ID: 9343324
[TBL] [Abstract][Full Text] [Related]
33. Molecular voting for glioma classification reflecting heterogeneity in the continuum of cancer progression.
Fuller GN; Mircean C; Tabus I; Taylor E; Sawaya R; Bruner JM; Shmulevich I; Zhang W
Oncol Rep; 2005 Sep; 14(3):651-6. PubMed ID: 16077969
[TBL] [Abstract][Full Text] [Related]
34. Beyond grade: molecular pathology of malignant gliomas.
Sulman EP; Guerrero M; Aldape K
Semin Radiat Oncol; 2009 Jul; 19(3):142-9. PubMed ID: 19464628
[TBL] [Abstract][Full Text] [Related]
35. Novel 3D magnetic resonance fingerprinting radiomics in adult brain tumors: a feasibility study.
Tippareddy C; Onyewadume L; Sloan AE; Wang GM; Patil NT; Hu S; Barnholtz-Sloan JS; Boyacıoğlu R; Gulani V; Sunshine J; Griswold M; Ma D; Badve C
Eur Radiol; 2023 Feb; 33(2):836-844. PubMed ID: 35999374
[TBL] [Abstract][Full Text] [Related]
36. DKK3 expression is associated with immunosuppression and poor prognosis in glioblastoma, in contrast to lower-grade gliomas.
Han MH; Baek JM; Min KW; Cheong JH; Ryu JI; Won YD; Kwon MJ; Koh SH
BMC Neurol; 2023 May; 23(1):183. PubMed ID: 37149563
[TBL] [Abstract][Full Text] [Related]
37. Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration.
M Hajj GN; da Silva FF; de Bellis B; Lupinacci FCS; Bellato HM; Cruz JR; Segundo CNC; Faquini IV; Torres LC; Sanematsu PI; Begnami MD; Martins VR; Roffé M
Mol Oncol; 2020 Jan; 14(1):159-179. PubMed ID: 31701625
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of the circadian clock network correlates with tumour progression in gliomas.
Petkovic M; Yalçin M; Heese O; Relógio A
BMC Med Genomics; 2023 Jul; 16(1):154. PubMed ID: 37400829
[TBL] [Abstract][Full Text] [Related]
39. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
[TBL] [Abstract][Full Text] [Related]
40. ELTD1, a potential new biomarker for gliomas.
Towner RA; Jensen RL; Colman H; Vaillant B; Smith N; Casteel R; Saunders D; Gillespie DL; Silasi-Mansat R; Lupu F; Giles CB; Wren JD
Neurosurgery; 2013 Jan; 72(1):77-90; discussion 91. PubMed ID: 23096411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
